{"id":838666,"date":"2025-04-17T09:14:01","date_gmt":"2025-04-17T13:14:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/"},"modified":"2025-04-17T09:14:01","modified_gmt":"2025-04-17T13:14:01","slug":"vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/","title":{"rendered":"Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Vistagen Presents New Research on the Impact of Social Anxiety Disorder <\/b><b>at The Anxiety and Depression Association 2025 Conference<\/b><\/p>\n<p class=\"bwalignc\"><i>New Data Build on Recent Epidemiology Findings Presented by the Company <\/i><i>at the 2024 Neuroscience Education Institute Congress<\/i><\/p>\n<p class=\"bwalignc\"><i>The Need for Improved Diagnosis and Treatment Options Underscored by Data Presented in Posters<\/i><\/p>\n<p>SOUTH SAN FRANCISCO, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vistagen.com%2F&amp;esheet=54239570&amp;newsitemid=20250417945756&amp;lan=en-US&amp;anchor=Vistagen&amp;index=1&amp;md5=849d0669e283529ef632b44014c8649c\">Vistagen<\/a> (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented new data on social anxiety disorder (SAD) at the 2025 Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada. The Company\u2019s poster presentations examined the age of onset of SAD in participants in the Company\u2019s fasedienol PALISADE Phase 3 program studies completed to date, as well as new data on the epidemiology of young adults with and without SAD from the National Health and Wellness survey (NHWS). The new research builds on epidemiology data on SAD prevalence and demographics presented by Vistagen at the 2024 Neuroscience Education Institute (NEI) Congress using the 2023 NHWS with over 75,000 respondents in the U.S.\n<\/p>\n<p>\n\u201cThis new research provides a clearer and more comprehensive picture of social anxiety disorder \u2014 shining light on its rising prevalence and significant impact on young adults,\u201d said Ross Baker, Ph.D., MBA, Vice President, Medical Strategy at Vistagen and a co-author of the research. \u201cExisting therapies remain limited, and these findings reinforce the urgent need for new treatment options. The new research also highlights the critical role of timely diagnosis to improve patient outcomes.\u201d\n<\/p>\n<p>\nThe key findings from the poster presentations by Vistagen at the ADAA and NEI conferences reveal important insights into SAD, including:\n<\/p>\n<p><b><span class=\"bwuline\">Overall prevalence<\/span><\/b>:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nSAD affects nearly 31 million adults in the U.S.\n<\/li>\n<li>\nThe prevalence of SAD overall among adults in the U.S. has increased over time, with the largest increase being among adults in the youngest age group (18\u201322 years).\n<\/li>\n<li>\nAlthough the rate of U.S. adults who experienced SAD has increased over time, the rate of SAD diagnosis has not increased, and treatment rates have decreased.\n<\/li>\n<li>\nMore than one in five U.S. adults surveyed who experienced SAD reported suicidal ideation on more than half the days in the past two weeks and worse mental health quality of life than the general U.S. adult population.\n<\/li>\n<li>\nOver three-quarters of those experiencing SAD reported mild to severe depression.\n<\/li>\n<\/ul>\n<p><b><span class=\"bwuline\">Subgroup aged 18-22<\/span><\/b>:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe prevalence of SAD experienced among U.S. young adults has increased over time, while the proportion of those treated for SAD has decreased.\n<\/li>\n<li>\nClose to half (48.1%) of U.S. young adults surveyed who reported experiencing SAD also reported suicidal ideation on at least several days in the past 2 weeks, markedly higher than those without SAD (31.6%).\n<\/li>\n<li>\nThose with SAD also had higher rates of depression and worse mental health quality of life than those without SAD.\n<\/li>\n<li>\nAmong those experiencing SAD, economic factors were generally worse than those not experiencing SAD: lower rates of full-time employment; significantly higher rates of household incomes lower than $50,000; and significantly greater impairment in productivity and activity.\n<\/li>\n<li>\nThese findings collectively elucidate the importance of diagnosing\/treating SAD and providing social support, as well as various alternative mechanisms to cope with SAD.\n<\/li>\n<\/ul>\n<p><b><span class=\"bwuline\">Age of onset of SAD in participants in Vistagen\u2019s fasedienol Phase 3 studies completed to date<\/span><\/b>:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nApproximately 30% of participants in Vistagen\u2019s<b \/>PALISADE Phase 3 Program studies of fasedienol nasal spray completed to date had a self-reported early onset of SAD in childhood, at 10 years of age or younger.\n<\/li>\n<li>\nRemarkably, the time to first treatment for SAD was, on average, 27 years from time of onset for the early-onset group and, on average, 18 years from onset for the adolescent\/adult-onset group, underscoring a high unmet need for diagnosis and treatment of SAD, especially among children and adolescents.\n<\/li>\n<li>\nBaseline severity of SAD and psychiatric and treatment histories were similar between early onset and adolescent\/adult-onset subjects.\n<\/li>\n<li>\nHistory of alcohol\/drug use was higher in the early-onset group than the adolescent\/adult-onset group.\n<\/li>\n<\/ul>\n<p><b><span class=\"bwuline\">Key Takeaways from this Research:<\/span><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nPromoting timely diagnosis and treatment of SAD is needed to improve various patient-reported outcomes, including physical and mental health and work productivity.\n<\/li>\n<li>\nApproved treatments for SAD are limited, and new treatments are needed.\n<\/li>\n<li>\nIn conjunction with treatments, providing young adults with social support and various alternative mechanisms to cope with SAD is imperative.\n<\/li>\n<li>\nConsumer education on the severity of SAD may also help drive discussions with healthcare providers.\n<\/li>\n<\/ul>\n<p>\nThe posters presented by Vistagen at the ADAA and NEI conferences are available on the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vistagen.com%2Fpublication&amp;esheet=54239570&amp;newsitemid=20250417945756&amp;lan=en-US&amp;anchor=Publications+page&amp;index=2&amp;md5=2b29ef593260250f2119f81616014f8a\">Publications page<\/a> of the Company\u2019s website.\n<\/p>\n<p><b>About Vistagen<\/b><\/p>\n<p>\nHeadquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a broad and diverse pipeline of clinical-stage product candidates from a new class of intranasal therapies called pherines.\n<\/p>\n<p>\nPherines specifically and selectively bind as agonists to peripheral receptors in human nasal chemosensory neurons, rapidly activating olfactory bulb-to-brain neurocircuits which regulate brain areas involved in behavior and autonomic nervous system activity. They achieve therapeutic benefits without requiring absorption into blood, or uptake into the brain, giving them a differentiated safety profile vs. other pharmacological options. Vistagen\u2019s neuroscience pipeline also includes an oral prodrug with potential to impact certain neurological conditions involving the NMDA receptor. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) associated with menopause. Connect at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.Vistagen.com&amp;esheet=54239570&amp;newsitemid=20250417945756&amp;lan=en-US&amp;anchor=www.Vistagen.com&amp;index=3&amp;md5=3f0c7c8a96ecca71400f8c618b1b0068\">www.Vistagen.com<\/a>.\n<\/p>\n<p><b>Forward-looking Statements<\/b><\/p>\n<p>\nThis press release contains certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as \u201cmay,\u201d \u201ccould,\u201d \u201cexpect,\u201d \u201cproject,\u201d \u201coutlook,\u201d \u201cstrategy,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cseek,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cstrive,\u201d \u201cgoal,\u201d \u201ccontinue,\u201d \u201clikely,\u201d \u201cwill,\u201d \u201cwould\u201d and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Vistagen and its management, are inherently uncertain. As with all pharmaceutical products, there are substantial risks and uncertainties in the process of development and commercialization and actual results or developments may differ materially from those projected or implied in these forward-looking statements. Among other things, there can be no guarantee that fasedienol or any of Vistagen\u2019s other product candidates will successfully complete ongoing or future clinical trials, receive regulatory approval or be commercially successful. These risks and others are more fully discussed in the section entitled \u201cRisk Factors\u201d in Vistagen\u2019s Annual Report on Form 10-K for the fiscal year ended March 31, 2024, and Quarterly Report on Form 10-Q for the period ended December 31, 2024, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the U.S. Securities and Exchange Commission (SEC). Vistagen\u2019s SEC filings are available on the SEC\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54239570&amp;newsitemid=20250417945756&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=4&amp;md5=8824df4a21dc5bec4e173fce101963d9\">www.sec.gov<\/a>. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing Vistagen\u2019s views as of any subsequent date. Vistagen explicitly disclaims any obligation to update any forward-looking statements other than as may be required by law. If Vistagen does update one or more forward-looking statements, no inference should be made that Vistagen will make additional updates with respect to those or other forward-looking statements.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250417945756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250417945756\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250417945756\/en\/<\/a><\/span><\/p>\n<p><b>Investor Inquiries:<br \/>\n<\/b><br \/>Mark A. McPartland<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:markmcp@vistagen.com\">markmcp@vistagen.com<\/a><\/p>\n<p><b>Media Inquiries:<br \/>\n<\/b><br \/>Michelle P. Wellington<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:mwellington@vistagen.com\">mwellington@vistagen.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health General Health Public Relations\/Investor Relations Pharmaceutical Communications Neurology Mental Health Research Science Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250417945756\/en\/1564398\/3\/Vistagen_Primary-Logo_Blue.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference New Data Build on Recent Epidemiology Findings Presented by the Company at the 2024 Neuroscience Education Institute Congress The Need for Improved Diagnosis and Treatment Options Underscored by Data Presented in Posters SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented new data on social anxiety disorder (SAD) at the 2025 Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada. The Company\u2019s poster presentations examined the age of onset of SAD in participants in the Company\u2019s fasedienol &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-838666","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference New Data Build on Recent Epidemiology Findings Presented by the Company at the 2024 Neuroscience Education Institute Congress The Need for Improved Diagnosis and Treatment Options Underscored by Data Presented in Posters SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented new data on social anxiety disorder (SAD) at the 2025 Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada. The Company\u2019s poster presentations examined the age of onset of SAD in participants in the Company\u2019s fasedienol &hellip; Continue reading &quot;Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-17T13:14:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250417945756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference\",\"datePublished\":\"2025-04-17T13:14:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\\\/\"},\"wordCount\":1341,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250417945756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\\\/\",\"name\":\"Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250417945756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-04-17T13:14:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250417945756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250417945756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/","og_locale":"en_US","og_type":"article","og_title":"Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - Market Newsdesk","og_description":"Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference New Data Build on Recent Epidemiology Findings Presented by the Company at the 2024 Neuroscience Education Institute Congress The Need for Improved Diagnosis and Treatment Options Underscored by Data Presented in Posters SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented new data on social anxiety disorder (SAD) at the 2025 Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada. The Company\u2019s poster presentations examined the age of onset of SAD in participants in the Company\u2019s fasedienol &hellip; Continue reading \"Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-17T13:14:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250417945756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference","datePublished":"2025-04-17T13:14:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/"},"wordCount":1341,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250417945756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/","name":"Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250417945756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-04-17T13:14:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250417945756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250417945756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-presents-new-research-on-the-impact-of-social-anxiety-disorder-at-the-anxiety-and-depression-association-2025-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/838666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=838666"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/838666\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=838666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=838666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=838666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}